First American Bank’s CRISPR Therapeutics CRSP Stock Holding History

First American Bank’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,333	Closed	-$204K	–	260
2020 Q4	$204K	Buy	+1,333	New	+$158K	0.01%	250
2018 Q4	–	Sell	-6,208	Closed	-$275K	–	317
2018 Q3	$275K	Buy	+6,208	New	+$325K	0.02%	297

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

First American Bank's CRSP Position: Q1 2021 in Review

First American Bank sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 1,333 shares — an estimated $204K sold.

First American Bank first reported a position in CRSP in Q3 2018 and held it in 2 quarters. The position peaked at $275K in Q3 2018. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

First American Bank reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
First American Bank sold 1,333 CRISPR Therapeutics shares in Q1 2021, an estimated $204K.
First American Bank first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 2 quarters.
First American Bank's CRISPR Therapeutics position peaked at $275K in Q3 2018.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on First American Bank's 13F filing for Q1 2021, filed 8 Apr 2021.